Last update 04 Nov 2024
Cefprozil
Last update 04 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Brisoral, Cefprozil (USP), Cefprozil anhydrous + [16] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (23 Dec 1991), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC18H21N3O6S |
InChIKeyALYUMNAHLSSTOU-PFBPGKLMSA-N |
CAS Registry121123-17-9 |
Related
49
Clinical Trials associated with CefprozilShort Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.
头孢丙烯片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉、空腹/餐后状态下生物等效性试验
[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-period, two-sequence, double-crossover, fasting/fed bioequivalence study of cefprozil tablets in healthy Chinese subjects
头孢丙烯片随机、开放、单剂量、两制剂、交叉设计在中国健康受试者中的生物等效性正式试验
[Translation] A randomized, open-label, single-dose, two-dose, crossover design formal bioequivalence trial of cefprozil tablets in Chinese healthy subjects
100 Clinical Results associated with Cefprozil
Login to view more data
100 Translational Medicine associated with Cefprozil
Login to view more data
100 Patents (Medical) associated with Cefprozil
Login to view more data
339
Literatures (Medical) associated with Cefprozil01 Feb 2024Therapeutic delivery
Aquasomes Nanoformulation for Controlled Release of Drug and Improved Effectiveness Against Bacterial Infections
Article
Author: Shanmugam, Bhuvaneshwari ; Srinivasan, Umashankar Marakanam
Aim: The study aimed to develop and evaluate an aquasome drug-delivery system for controlled drug delivery of cefprozil monohydrate. Materials & methods: Aquasomes were prepared by the spinal method with a calcium phosphate core, sugar-coated using cellobiose and drug-loaded by adsorption. The formulations were characterized for size, morphology and drug release. An antibacterial study was conducted for Gram-positive and -negative bacteria. Results: It showed particle size of 2791.9 nm, zeta potential of -0.3 mV with good stability, and 99.08% of drug loading and drug release were controlled and prolonged, achieving 56% within 8 h and possessing potential for 100% release beyond 12 h. Conclusion: An aquasome drug-delivery system was developed for novel controlled drug delivery for pharmaceutical antibiotic therapeutics.
01 Jan 2024Medical Bulletin of Sisli Etfal Hospital
Evaluation of Cross-Reactivity Between Penicillins and Cephalosporins in Children with a History of Cephalosporin Allergy
Article
Author: Cetinkaya, Feyzullah ; Kutluk, Gunsel ; Eker, Nursah
Objectives:
The cross-reactivity problem between cephalosporins and penicillins has mainly been evaluated in the context of patients allergic to penicillins. However, we have little data regarding the opposite aspect of the problem, i.e. the cross-reactivity in subjects primarily sensitized to cephalosporins. This prospective study aims to evaluate the cross-reactivity to penicillins and some other cephalosporins in patients with immediate allergic reactions to cephalosporins.
Methods:
The study included 21 children with immediate allergic reactions to at least one cephalosporin. Skin testing was performed with a panel of minor and major determinant mixtures of penicillins and three commonly used cephalosporins (cephazoline, cefuroxime and ceftriaxone).
Results:
The children had used 5.14±4.91 (1-15) times any beta-lactam antibiotic in the previous year and the most common cephalosporins accused were ceftriaxone (42.92%), and cefuroxime, cefazolin, cefixime, cefprozil and cefotaxime (9.5% each). Skin tests were positive for any cephalosporin in 14 (66.7%) subjects and penicillin allergens in 15 (71.4%) subjects. Totally, 85.7% of children with a positive allergy history to cephalosporins were found to be sensitive to either penicillin or any one of three cephalosporins.
Conclusion:
There seems to be a high risk of adverse reactions to penicillins and other cephalosporins in children with a history of type I hypersensitivity reaction to cephalosporins. Therefore, skin testing with both cephalosporins and penicillins should be performed in patients with a history of cephalosporin allergy.
01 Jan 2024The journal of allergy and clinical immunology. In practice
Assessing Pediatric Cephalosporin Allergic Reactions Through Direct Graded Oral Challenges
Article
Author: Kim, Vy ; Gabrielli, Sofianne ; McCusker, Christine ; O'Keefe, Andrew ; Ben-Shoshan, Moshe ; Atkinson, Adelle ; Abrams, Elissa M ; Sillcox, Carly ; Eiwegger, Thomas ; Copaescu, Ana-Maria
BACKGROUND:
Cephalosporins, β-lactam antibiotics, commonly cause allergic reactions.
OBJECTIVE:
To assess the clinical characteristics and management of pediatric patients with suspected cephalosporin allergy using direct graded oral challenges (GOCs).
METHODS:
Children referred for suspected cephalosporin allergy at 4 Canadian clinics were recruited over 10 years. Data on demographics, clinical reaction characteristics, and management were collected through a questionnaire. Patients underwent a direct GOC (initially 10% of the treatment dose, then 90% after 20 min), and reactions were monitored 1 week postchallenge. Families were contacted annually for up to 5 years to detect subsequent antibiotic reactions. Logistic regression analysis identified factors associated with positive GOC reactions.
RESULTS:
Among the 136 patients reporting cephalosporin allergy, 75 (55.1%) were males with a median age of 3.9 years (interquartile range 2.3-8.7). Cefprozil represented the most common cephalosporin linked to the index reaction (67.6% of cases). Of the 136 direct GOCs, 5.1% had an immediate and 4.4% a nonimmediate reaction, respectively. Positive GOCs conducted in children with a history of skin-limited nonsevere rashes were classified as mild, benign skin rashes. Positive GOCs were more likely in children with food allergies (adjusted odds ratio 1.14; 95% confidence interval [95% CI] 1.00-1.29).
CONCLUSIONS:
Direct GOCs are safe and effective for diagnosing pediatric cases that report nonvesicular skin-limited symptoms while being treated with cephalosporins.
100 Deals associated with Cefprozil
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Respiratory Tract Infections | FR | - | 02 Nov 1997 |
| Bacterial Infections | CH | - | 28 Dec 1996 |
| Gram-Negative Bacterial Infections | US | 23 Dec 1991 | |
| Gram-Positive Bacterial Infections | US | 23 Dec 1991 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 60 | rbwqbtovuo(sozfwgfydh) = bbarhzuzae jwfssweimc (dofqtadtij ) View more | - | 01 Feb 2021 | ||
Granule Formulation | rbwqbtovuo(sozfwgfydh) = oyluqopslw jwfssweimc (dofqtadtij ) View more | ||||||
Phase 1 | - | 39 | (Cefprozil (Test)) | sswsvtewyq(ywtrtmfstq) = mccsvouccd cvfbgfzozo (nshuxernda, csulzebvgz - pykjoggfld) View more | - | 21 Jul 2009 | |
(Cefzil® (Reference)) | sswsvtewyq(ywtrtmfstq) = lwfdotttcr cvfbgfzozo (nshuxernda, qymlryvsmg - zvptsggvxi) View more | ||||||
Phase 1 | - | 26 | (Cefprozil (Test)) | eiasfwulnq(nqxxrrpeqr) = pszjjtohgd njvizomeup (wuuxhokdir, ieghvvzhiu - vpgsdevexm) View more | - | 21 Jul 2009 | |
(Cefzil® (Reference)) | eiasfwulnq(nqxxrrpeqr) = fgqxdnqfdn njvizomeup (wuuxhokdir, vlehymkiel - knffyrncqa) View more | ||||||
Phase 1 | - | 38 | (Cefprozil (Test)) | dsxtgzcyrg(ndllfhnrky) = wlozymkekc lrzuppwxef (tagsehowip, ulhpuvmnaa - dowvqeczwj) View more | - | 21 Jul 2009 | |
(Cefzil® (Reference)) | dsxtgzcyrg(ndllfhnrky) = nqymulkcps lrzuppwxef (tagsehowip, baowbmcghd - semcbyygqi) View more | ||||||
Phase 1 | - | 26 | (Cefprozil (Test)) | midbxlrezd(kabwuivodm) = efwesakfqd fiafrjbtrs (ooaxcjgleo, fjzbrcfubz - ajdosrxkiy) View more | - | 21 Jul 2009 | |
(Cefzil® (Reference)) | midbxlrezd(kabwuivodm) = rdjsmjhzfw fiafrjbtrs (ooaxcjgleo, thvygetkda - jrsxaudidv) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free